PI3K-mediated PDGFRα signaling regulates survival and proliferation in skeletal development through p53-dependent intracellular pathways

Genes and Development

Volumn 28, Issue 9, 2014, Pages 1005-1017

  Fantauzzo, Katherine A ^a   Soriano, Philippe ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

p53; PDGFR ; PI3K; Proliferation; Skeleton; Survival

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; PROTEIN KINASE B; PROTEIN P53; TRP53 PROTEIN; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CELL LYSATE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; IMMUNOPRECIPITATION; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIQUID CHROMATOGRAPHY; MESENCHYME CELL; MOUSE; MOUSE EMBRYONIC PALATAL MESENCHYME CELL; NEWBORN; NONHUMAN; NULL ALLELE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TANDEM MASS SPECTROMETRY; VERTEBRA MALFORMATION; WILD TYPE;

P53; PDGFRΑ; PI3K; PROLIFERATION; SKELETON; SURVIVAL;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; EMBRYO, MAMMALIAN; GENE KNOCK-IN TECHNIQUES; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899753442     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.238709.114     Document Type: Article

References (52)

1. Aizawa R., Yamada A, Suzuki D, Iimura T, Kassai H, Harada T, Tsukasaki M., Yamamoto G, Tachikawa T, Nakao K, et al. 2012. Cdc42 is required for chondrogenesis and interdigital programmed cell death during limb development. Mech Dev 129: 38-50.
2. Alessi D. R, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. 1996. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 399: 333-338.
3. Andrae J., Gallini R, Betsholtz C. 2008. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 14: 731-737.
4. Bauerfeld C. P, Hershenson MB, Page K. 2001. Cdc42, but not RhoA, regulates cyclin D1 expression in bovine tracheal myocytes. Am J Physiol Lung Cell Mol Physiol 280: L974-L982.
5. Brachmann S. M, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, Cantley LC. 2005. Role of phosphoinositide 3-kindase regulatory isoforms in development and actin rearrangement. Mol Cell Biol 25: 2593-2606.
6. Bush J. O, Soriano P. 2010. Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph-ephrin boundaries. Genes Dev 24: 2068-2080.
7. Chakraborty M., Qiu SG, Vasudevan KM, Rangnekar VM. 2001. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 61: 7255-7263.
8. Chen E. Y, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. 2013. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14: 128.
9. Didier D. K, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. 1988. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci 85: 7322-7326.
10. Ding H., Wu X, Boström H, Kim I, Wong N, Tsoi B, O'Rourke M, Koh G. Y, Soriano P, Betsholtz C, et al. 2004. A specific requirement for PDGF-C in palate formation and PDGFR-a signaling. Nat Genet 36: 1111-1116.
11. Dixon J., Hovanes K, Shiang R, Dixon MJ. 1997. Sequence analysis, identification of evolutionary conserved motifs and expression analysis of murine tcof1 provide further evidence for a potential function for the gene and its human homologue, TCOF1. Hum Mol Genet 6: 727-737.
12. Dixon J., Jones NC, Sandell LL, Jayasinghe SM, Crane J, Rey J-P, Dixon M. J, Trainor PA. 2006. Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofacial abnormalities. Proc Natl Acad Sci 103: 13403-13408.
13. El-Guendy N., Rangnekar VM. 2003. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 283: 51-66.
14. Fowles L. F, Bennetts JS, Berkman JL, Williams E, Koopman P, Teasdale R. D, Wicking C. 2003. Genomic screen for genes involved in mammalian craniofacial development. Genesis 35: 73-87.
15. Fuchs S., Herzog D, Sumara G, Büchmann-Moller S, Civenni G, Wu X., Chrostek-Grashoff A, Suter U, Ricci R, Relvas JB, et al. 2009. Stage-specific control of neural crest stem cell proliferation by the small Rho GTPases Cdc42 and Rac1. Cell Stem Cell 4: 236-247.
16. Gu Y-M, Jin Y-H, Choi J-K, Baek K-H, Yeo C-Y, Lee K-Y. 2006. Protein kinase A phosphorylates and regulates dimerization of 14-3-3ζ. FEBS Lett 580: 305-310.
17. Hamilton T. G, Klinghoffer RA, Corrin PD, Soriano P. 2003. Evolutionary divergence of platelet-derived growth factor a receptor signaling mechanisms. Mol Cell Biol 23: 4013-4025.
18. He F., Soriano P. 2013. A critical role for PDGFRa signaling in medial nasal process development. PLoS Genet 9: e1003851.
19. Heldin C. H, Westermark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
20. Homer C., Knight DA, Hananeia L, Sheard P, Risk J, Lasham A, Royds J. A, Braithwaite AW. 2005. Y-box factor YB1 controls p53 apoptotic function. Oncogene 24: 8314-8325.
21. Jacks T., Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson R. T, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
22. Jones N. C, Lynn ML, Gaudenz K, Sakai D, Aoto K, Rey J-P, Glynn E. F, Ellington L, Du C, Dixon J, et al. 2008. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat Med 14: 125-133.
23. Joosten P. H, Toepoel M, Mariman EC, Van Zoelen EJ. 2001. Promoter haplotype combinations of the platelet-derived growth factor a-receptor gene predispose to human neural tube defects. Nat Genet 27: 215-217.
24. Joyner A., Wall N. 2008. Immunohistochemistry of whole-mount mouse embryos. Cold Spring Harb Protoc 2008: pdb. prot4820.
25. Jurchott K., Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G., Fietze E, Dietel M, Royer HD. 2003. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278: 27988-27996.
26. Kebache S., Ash J, Annis MG, Hagan J, Huber M, Hassard J, Stewart C. L, Whiteway M, Nantel A. 2007. Grb10 and active Raf-1 kinase promote Bad-dependent cell survival. J Biol Chem 282: 21873-21883.
27. Kerrien S., Aranda B, Breuza L, Bridge A, Broackes-Carter F, Chen C, Duesbury M, Dumousseau M, Feuermann M, Hinz U, et al. 2012. The IntAct molecular interaction database in 2012. Nucleic Acids Res 40: D841-D846.
28. Klinghoffer R. A, Hamilton TG, Hoch R, Soriano P. 2002. An allelic series at the PDGFaR locus indicates unequal contributions of distinct signaling pathways during development. Dev Cell 2: 103-113.
29. Kurdistani S. K, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee S.W. 1998. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res 58: 4439-4444.
30. Lasham A., Lindridge E, Rudert F, Onrust R, Watson J. 2000. Regulation of the human fas promoter by YB-1, Pura and AP-1 transcription factors. Gene 252: 1-13.
31. Lasham A., Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite A. W, Watson J. 2003. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem 278: 35516-35523.
32. Manning B. D, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
33. Mertens P. R, Harendza S, Pollock AS, Lovett DH. 1997. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem 272: 22905-22912.
34. Moritz A., Li Y, Guo A, Villén J, Wang Y, MacNeill J, Kornhauser J, Sprott K, Zhou J, Possemato A, et al. 2010. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal 3: ra64.
35. Okuda T., Higashi Y, Kokame K, Tanaka C, Kondoh H, Miyata T. 2004. Ndrg1-deficient mice exhibit a progressive demyelinating disorder of peripheral nerves. Mol Cell Biol 24: 3949-3956.
36. Pickett E., Olsen GS, Tallquist MD. 2008. Disruption of PDGFRa-initiated PI3K activation and migration of somite derivatives leads to spina bifida. Development 135: 589-598.
37. Ralphs J.R. 1992. Chondrogenesis and myogenesis in micromass cultures of mesenchyme from mouse facial primordia. In Vitro Cell Dev Biol 28A: 369-372.
38. Rattanasopha S., Tongkobpetch S, Srichomthong C, Siriwan P, Subhapeetiporn K., Shotelersuk V. 2012. PDGFRa mutations in humans with isolated cleft palate. Eur J Hum Genet 20: 1058-1062.
39. Rinon A., Molchadsky A, Nathan E, Yovel G, Rotter V, Sarig R, Tzahor E. 2011. p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. Development 138: 1827-1838.
40. Rosenkranz S., DeMali KA, Gelderloos JA, Bazenet C, Kazlauskas A. 1999. Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J Biol Chem 274: 28335-28343.
41. Sah V. P, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. 1995. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 10: 175-180.
42. Soriano P. 1997. The PDGF a receptor is required for neural crest cell development and for normal patterning of the somites. Development 124: 2691-2700.
43. Stein S., Thomas EK, Herzog B, Westfall MD, Rocheleau JV, Jackson RS II, Wang M, Liang P. 2004. NDRG1 is necessary for p53-dependent apoptosis. J Biol Chem 279: 48930-48940.
44. Sutherland B. W, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D., Dedhar S, Nelson C, Pollak M, et al. 2005. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-4292.
45. Tallquist M. D, Weismann KE, Hellström M, Soriano P. 2000. Early myotome specification regulates PDGFA expression and axial skeleton development. Development 127: 5059-5070.
46. The Treacher Collins Syndrome Collaborative Group. 1996. Positional cloning of a gene involved in the pathogenesis of Treacher Collins syndrome. Nat Genet 12: 130-136.
47. Uchiumi T., Fotovati A, Sasaguri T, Shibahara K, Shimada T, Fukuda T., Nakamura T, Izumi H, Tsuzuki T, Kuwano M, et al. 2006. YB-1 is important for an early stage embryonic development: neural tube formation and cell proliferation. J Biol Chem 281: 40440-40449.
48. Vantler M., Huntgeburth M, Caglayan E, ten Freyhaus H, Schnabel P., Rosenkranz S. 2006. PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGFa receptor is negatively regulated by Src family kinases. FEBS Lett 580: 6769-6776.
49. Vasudevan K. M, Garraway LA. 2010. AKT signaling in physiology and disease. Curr Top Microbiol Immunol 347: 105-133.
50. Yu J. C, Heidaran MA, Pierce JH, Gutkind JS, Lombardi D, Ruggiero M., Aaronson SA. 1991. Tyrosine mutations within the a platelet-derived growth factor receptor kinase insert domain abrogate receptor-associated phosphatidylinositol-3 kinase activity without affecting mitogenic or chemotactic signaling transduction. Mol Cell Biol 11: 3780-3785.
51. Zhang H., Zha X, Tan Y, Hornbeck PV, Mastrangelo AJ, Alessi DR, Polakiewicz RD, Comb MJ. 2002. Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs. J Biol Chem277: 39379-39387.
52. Zhou A., Ou AC, Cho A, Benz EJ Jr, Huang SC. 2008. Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5 splice site selection. Mol Cell Biol 28: 5924-5936.